Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors

被引：0

作者：

Denker, S. ^{[1
,2
]}

Bittner, A. ^{[1
,2
]}

Frick, M. ^{[1
]}

Kase, J. ^{[1
]}

Hoffmann, J. ^{[3
]}

Trenker, C. ^{[3
]}

Keller, U. ^{[2
,4
,5
,6
,7
]}

Bogner, C. ^{[8
]}

Huttmann, A. ^{[9
]}

Duhrig, J. ^{[9
]}

Janz, M. ^{[4
,7
]}

Mathas, S. ^{[4
,7
]}

Marks, R. ^{[10
,11
]}

Krohn, U. ^{[10
,11
]}

Bhattacharya, A. ^{[4
]}

Na, I. -K ^{[1
,2
]}

Gebauer, B. ^{[4
]}

Savic, L. J. ^{[4
]}

Hubner, N. ^{[7
]}

Akalin, A. ^{[12
]}

Eils, R. ^{[2
]}

Bullinger, L. ^{[1
,2
,5
,6
]}

Schmitt, C. A. ^{[1
,7
,13
]}

机构：

[1] Charite Univ Med Berlin, Med Klin mS Hamatol Onkol & Tumorimmunol, Campus Virchow Klinikum, Berlin, Germany

[2] Berlin Inst Hlth BIH, Berlin, Germany

[3] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol, Oncol,Immunol, Marburg, Germany

[4] Charite Univ Med Berlin, Berlin, Germany

[5] German Canc Res Ctr, Heidelberg, Germany

[6] German Canc Consortium DKTK, Heidelberg, Germany

[7] Max Delbruck Ctr Mol Med, Berlin, Germany

[8] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany

[9] Univ Duisburg Essen, Univ Klinikum Essen, Klin Hamatol, Essen, Germany

[10] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Fac Med, Freiburg, Germany

[11] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Med Ctr, Freiburg, Germany

[12] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Bioinformat & Omics Data Sci Platform, Berlin, Germany

[13] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V104

引用

页码：24 / 24

页数：1

共 50 条

[41] Assessment of Circulating Tumor DNA in Newly Diagnosed DLBCL Patients Randomly Treated By R-CHOP or R-High Dose Chemotherapy Plus Autologous Stem Cell Support
Desmots-Loyer, Fabienne
Rossille, Delphine
Roussel, Mikael
Le Gouill, Steven
Lamy, Thierry
Milpied, Noel
Fest, Thierry
BLOOD, 2021, 138
[42] Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
Villacampa, Guillermo
Dienstmann, Rodrigo
Bosch, Francesc
Abrisqueta, Pau
ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2969 - 2978
[43] Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
Guillermo Villacampa
Rodrigo Dienstmann
Francesc Bosch
Pau Abrisqueta
Annals of Hematology, 2021, 100 : 2969 - 2978
[44] Orelabrutinib Plus R-CHOP Regimen in Treatment-Naive Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)
Xiao, Yi
Wu, Jiaying
Zhou, Mi
Shang, Zhen
Zhu, Ming
BLOOD, 2023, 142
[45] frontMIND: A phase III, randomized, double-blind study of tafasitamab plus lenalidomide plus R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
Vitolo, Umberto
Nowakowski, Grzegorz S.
Burke, John M.
Fox, Christopher P.
Trneny, Marek
Chiappella, Annalisa
Waldron-Lynch, Maeve
Hadar, Nira
Pachori, Alok
Lenz, Georg
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab plus Lenalidomide plus R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
Vitolo, Umberto
Nowakowski, Grzegorz S.
Burke, John M.
Fox, Christopher P.
Trneny, Marek
Chiappella, Annalisa
Waldron-Lynch, Maeve
Wagner, Steve
Pachori, Alok
Lenz, Georg
BLOOD, 2022, 140 : 6618 - 6620
[47] Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
Hoffmann, Marc
Vassilakopoulos, Theodoros
Munoz, Javier
Westin, Jason R.
Bouzani, Maria
Jurczak, Wojciech
Kwiatek, Michal
Berkovits, Alejandro
Huang, Tai-Chung
Sudhindra, Akshay
Patel, Arpankumar
Boucaud, Floriane
Petel, Adrien
Nowakowski, Grzegorz S.
BLOOD, 2024, 144
[48] Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).
Nowakowski, Grzegorz S.
Chiappella, Annalisa
Witzig, Thomas E.
Spina, Michele
Gascoyne, Randy D.
Zhang, Lei
Flament, Jocelyne
Repici, Jacqueline
Conlin, Erin
Delissio, Krista
Vitolo, Umberto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[49] Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
Mu-Chen Zhang
Ying Fang
Li Wang
Shu Cheng
Di Fu
Yang He
Yan Zhao
Chao-Fu Wang
Xu-Feng Jiang
Qi Song
Peng-Peng Xu
Wei-Li Zhao
Clinical Epigenetics, 2020, 12
[50] Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
Zhang, Mu-Chen
Fang, Ying
Wang, Li
Cheng, Shu
Fu, Di
He, Yang
Zhao, Yan
Wang, Chao-Fu
Jiang, Xu-Feng
Song, Qi
Xu, Peng-Peng
Zhao, Wei-Li
CLINICAL EPIGENETICS, 2020, 12 (01)

← 1 2 3 4 5 →